EUVIMEDOpdag EUVIMED
Crossref

Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy

Wen-Hui Liu, Chen-Lin Xiao, Zhi-Ying Luo, Ya-Jun Zhu, Wen-Ru Li, Huan Ren, Zhen Guo, Jian-Quan Luo

British Journal of Pharmacology · 2026-08 · 183 (16) · 4562-4575

DOI: 10.1111/bph.70472 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-04-30. Written by Wen-Hui Liu and 7 co-authors. Institution: Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China. Major MEDLINE topics: Bifidobacterium, Lactose, Immunotherapy, Neoplasms. 47 references. Funded by: Chinese Pharmaceutical Association Hospital Pharmacy Department, National Natural Science Foundation of China, Scientific Foundation of Hunan.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose The potential predictive and therapeutic value of Bifidobacterium in immune checkpoint inhibitor (ICI) treatment has been widely studied. However, the value of its genetic determinants on the prognosis of ICI treatment remains unclear. Experimental Approach We examined the associations between 11 single nucleotide polymorphisms (SNPs) located at host genes associated with Bifidobacterium abundance and the outcomes of ICI treatment in 370 eligible Chinese cancer patients. Key Results LCT/MCM6 SNPs, rs3739020, rs3739022, rs56263017 and rs55809728, were strongly associated with overall survival (OS), and the LCT haplotype analysis showed that genetically predicted lactose poor metabolisers exhibited significantly poorer OS ( P ‐value = 0.002, adjusted HR = 0.45, 95%CI = 0.27–0.74). In polygenic SNP analysis, the genetically inferred high galactose level carriers exhibited significantly prolonged OS ( P ‐value = 0.007, adjusted HR = 0.32, 95%CI = 0.14–0.73) and progression‐free survival (PFS, P ‐value = 0.001, adjusted HR = 0.45, 95%CI = 0.29–0.71). All four SNPs and the lactose metabolic phenotype were not associated with the occurrence of overall immune‐related adverse events (irAEs). Two‐sample mendelian randomisation analysis showed genetically predicted Bifidobacterium abundance correlated with lactose metabolism pathway abundance ( P value = 0.012, Beta coefficient = 0.549). Conclusions and Implications Lactose metabolism pathway SNPs, which are linked to Bifidobacterium abundance in prior studies, have prognostic value for immunotherapy efficacy in Chinese cancer patients, and the genetically predicted lactose extensive and intermediate metabolisers exhibited better immunotherapy efficacy. These findings remain exploratory and require further validation with direct microbiome and metabolite measurements.

Subjects

MeSH terms (MEDLINE)

BifidobacteriumLactoseImmunotherapyNeoplasmsImmune Checkpoint InhibitorsHumansPolymorphism, Single NucleotideFemalePrognosisMaleMiddle AgedAged

Author keywords

efficacygut microbiotaimmune checkpoint inhibitorsimmune‐related adverse eventslactose metabolismpharmacogenomics

Substances

LactoseImmune Checkpoint Inhibitors

Authors and institutions

  • Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.
  • Institute of Clinical Pharmacy, Central South University, Changsha, China.
  • Hunan Pharmaceutical Development Investment Group Co., Ltd., Changsha, China.
  • Department of Pharmacy, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
  • Hunan Provincial Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University, Changsha, China.

Funding

  • Chinese Pharmaceutical Association Hospital Pharmacy Department
  • National Natural Science Foundation of China
  • Scientific Foundation of Hunan
  • Degree & Postgraduate Education Reform Project of Central South University

Cite

APA

Liu, W. H., Xiao, C. L., Luo, Z. Y., Zhu, Y. J., Li, W. R., Ren, H., Guo, Z., & Luo, J. Q. (2026). Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy. British Journal of Pharmacology, 183(16), 4562-4575. https://doi.org/10.1111/bph.70472

Vancouver

Liu WH, Xiao CL, Luo ZY, Zhu YJ, Li WR, Ren H, et al. Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy. British Journal of Pharmacology. 2026;183(16):4562-4575. doi:10.1111/bph.70472

BibTeX
@article{Liu2026,
  author = {Liu, Wen-Hui and Xiao, Chen-Lin and Luo, Zhi-Ying and Zhu, Ya-Jun and Li, Wen-Ru and Ren, Huan and Guo, Zhen and Luo, Jian-Quan},
  title = {Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {16},
  pages = {4562--4575},
  doi = {10.1111/bph.70472}
}
Start for free →